^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BP1002

    i
    Other names: BP1002, BP-100-1.02, L-Bcl-2 antisense oligonucleotide, liposomal Bcl2
    Associations

    News

    Trials
    Company:
    Bio-Path
    Drug class:
    Bcl2 inhibitor
    Related drugs:
    Associations

    News

    Trials
    3ms
    A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies (clinicaltrials.gov)
    P1, N=30, Recruiting, Bio-Path Holdings, Inc. | Trial completion date: Jan 2025 --> Jan 2026
    Trial completion date • Metastases
    |
    BCL2 expression
    |
    BP1002
    7ms
    A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies (clinicaltrials.gov)
    P1, N=30, Recruiting, Bio-Path Holdings, Inc. | Trial completion date: Jan 2024 --> Jan 2025 | Trial primary completion date: Sep 2023 --> Sep 2024
    Trial completion date • Trial primary completion date • IO biomarker • Metastases
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    BCL2 expression
    |
    BP1002
    over1year
    A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML) (clinicaltrials.gov)
    P1, N=48, Recruiting, Bio-Path Holdings, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    decitabine • BP1002
    almost2years
    A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML) (clinicaltrials.gov)
    P1, N=48, Not yet recruiting, Bio-Path Holdings, Inc. | Initiation date: Apr 2022 --> Jul 2022
    Trial initiation date
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    decitabine • BP1002
    2years
    A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies (clinicaltrials.gov)
    P1, N=30, Recruiting, Bio-Path Holdings, Inc. | Trial completion date: Aug 2022 --> Jan 2024 | Trial primary completion date: Feb 2022 --> Sep 2023
    Trial completion date • Trial primary completion date • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    BCL2 expression
    |
    BP1002
    2years
    A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML) (clinicaltrials.gov)
    P1, N=48, Not yet recruiting, Bio-Path Holdings, Inc. | Initiation date: Jan 2022 --> Apr 2022
    Trial initiation date
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    decitabine • BP1002
    over2years
    A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML) (clinicaltrials.gov)
    P1, N=48, Not yet recruiting, Bio-Path Holdings, Inc.
    New P1 trial
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    decitabine • BP1002
    3years
    [VIRTUAL] The combination of liposomal Bcl-2 antisense oligonucleotide (BP1002) with decitabine is efficacious in venetoclax-resistant cells (AACR 2021)
    Our data indicate that, despite expressing higher levels of anti-apoptotic proteins, venetoclax-resistant cells are sensitive to the BP1002 plus decitabine combination. These promising preclinical results suggest that the BP1002 plus decitabine combination is a potential treatment for patients who have relapsed from frontline venetoclax-based therapies.
    IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • MCL1 (Myeloid cell leukemia 1)
    |
    BCL2 expression
    |
    Venclexta (venetoclax) • decitabine • BP1002
    over3years
    A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies (clinicaltrials.gov)
    P1, N=30, Recruiting, Bio-Path Holdings, Inc. | Trial completion date: Aug 2021 --> Aug 2022 | Trial primary completion date: Feb 2021 --> Feb 2022
    Clinical • Trial completion date • Trial primary completion date • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    BCL2 expression
    |
    BP1002
    almost4years
    A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, Bio-Path Holdings, Inc. | Initiation date: Feb 2020 --> Jun 2020
    Clinical • Trial initiation date • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    BCL2 expression
    |
    BP1002
    4years
    [VIRTUAL] A phase I clinical trial to study the safety, pharmacokinetics, and efficacy of BP1002 (L-Bcl-2) antisense oligonucleotide in patients with advanced lymphoid malignancies (AACR-I 2020)
    The dose below that will be the maximum tolerated dose (MTD). The RP2D will be determined using the MTD data and all information regarding safety, biological activity, PK and pharmacodynamics.Primary objectives: To determine•Safety and tolerability of escalating doses of BP1002•RP2D of BP1002•PK of BP1002•BP1002 activity on Bcl-2 expressionSecondary objectives: To obtain evidence of tumor response (overall response rate = complete remission + partial remission + minor response), and estimates for other response parameters (time to progression, progression-free survival, event-free survival)Exploratory objectives: To correlate treatment response with biological activity, cytogenetic and molecular characteristicsSafety assessments will include identification of DLTs, serious adverse events, treatment-emergent adverse events and treatment-emergent laboratory abnormalitiesResponse assessments will be determined per the 2018 International Workshop Group on CLL (iwCLL) response criteria, the International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017), or the Eighth International Workshop for Waldenströms Macroglobulinemia response criteria.
    Clinical • P1 data • PK/PD data • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    BP1002